Suvorexant considered for Restless Legs Syndrome treatment to avoid dopamine agonist augmentation

Restless Legs Syndrome (RLS) is a neurological disorder causing an irresistible urge to move the legs, often worse at night, disrupting sleep. Current standard-of-care often involves dopamine agonists, which can lead to symptom augmentation—a worsening or earlier onset of RLS symptoms over time. This limits their long-term efficacy. Orexin (hypocretin) neuropeptides regulate sleep/wakefulness. Antagonizing the orexin system promotes slow-wave sleep and reduces wakefulness, suggesting a potential role in sleep-related disorders like RLS.

This abstract outlines the rationale for investigating Suvorexant as a treatment for Restless Legs Syndrome (RLS), highlighting the limitations of current therapies. It does not present a specific study design or experimental protocol for RLS, but rather discusses the theoretical basis for its potential efficacy, drawing on its known effects on sleep and the orexin system. The authors consider that Suvorexant might provide a stable therapeutic efficacy for long-term RLS treatment.

While this abstract does not present novel findings for Restless Legs Syndrome (RLS), it references the established efficacy of Suvorexant for primary insomnia. Suvorexant is FDA approved for this condition, demonstrating improvements in sleep latency and wake after sleep onset (WASO).

Investigators hypothesize that Suvorexant might offer a stable therapeutic efficacy for RLS, specifically by avoiding the common risk of symptom augmentation seen with long-term dopamine agonist use. This consideration is based on the known role of the orexin system in sleep regulation and the potential for orexin receptor antagonism to stabilize sleep architecture, which could indirectly benefit RLS patients by improving sleep quality without exacerbating motor symptoms.